J clin oncol. 2010 28 27 : 4184-90

Author: qhuo

August undefined, 2024

WebApr 11, 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal treatment options for recurrent platinum-resistant ovarian cancer.MethodsPubmed, … WebJun 8, 2024 · Front. Oncol. 2024; 9: 591. 7 Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J. Clin. Oncol. 2010; 28: 311–7. 8 Kutikov A, Egleston BL, Canter D, Smaldone MC, Wong YN, Uzzo RG.

National Center for Biotechnology Information

WebCPIC guidelines suggest an initial 90% dose reduction in homozygous variant patients and a 30%–70% dose reduction in heterozygous patients. Based on the FDA label for 6-MP, ... J … WebMay 15, 2004 · Three of the 28 responding patients did not undergo ASCT: 1 patient refused, one patient did not have an adequate number of mobilized stem cells and underwent allogeneic transplantation from his HLA-matched sibling, and one patient, who did not have any mobilized PBPCs even after a repeated attempt with G-CSF alone, was found to have … empty suzanne weyn summary

Meta-analysis of concomitant versus sequential …

Web合肥复发难治治疗.ppt,毒副反应 Crump M, et al. J Clin Oncol 2014;32:3490 第二十九页，共六十六页，2024年，8月28日美罗华在移植动员中的净化作用：大剂量美罗华+BEAM 移植动员方案利妥昔单抗：动员化疗前1天，375mg/m2 静脉给药，化疗后7天，1000mg/m2 静脉给药，移植后d1和d8， 1000mg/m2 静脉给药。 WebJan 7, 2024 · Oncol. 28, 4184–90 (2010). Article Google Scholar Qualls, D. & Abramson, J. S. Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma. WebJun 8, 2024 · J Clin Oncol. 2010;28 (27):4184–90. (1iiDiv/1iiA). 13. Mey UJ, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as … drax golf club selby

Outcome of patients with relapsed diffuse large B-cell ... - Nature

Hematological Oncology: List of Issues - Wiley Online Library

WebMay 1, 2010 · J Clin Oncol. 2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29. Authors Anne Aupérin 1 , Cecile Le Péchoux, Estelle Rolland, Walter J Curran, Kiyoyuki Furuse, Pierre Fournel, Jose Belderbos, Gerald Clamon, Hakki Cuneyt Ulutin, Rebecca Paulus ... WebJ Clin Oncol. 1999;17:3776–3785. 4. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190. 5. empty swingWebApr 13, 2024 · Patients aged 70 years or older with low-risk breast cancer (BrC), i.e., clinically axillary node-negative, oestrogen and/or progesterone receptor-positive (hormone receptor-positive, HR+) BrC, have a 10-year disease-specific survival rate of about 98% [].This fact notwithstanding and despite their substantial risk of toxicity and adverse medical effects, … drax generation capacity

"WebGisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., … Schmitz, N. (2010). Salvage Regimens With Autologous Transplantation for ... " - J clin oncol. 2010 28 27 : 4184-90

J clin oncol. 2010 28 27 : 4184-90

Outcome of patients with relapsed diffuse large B-cell

WebJul 26, 2010 · Volume 28, Issue 27 > ORIGINAL REPORTS Hematologic Malignancies DOI: 10.1200/JCO.2010.28.1618 Journal of Clinical Oncology - published online before print … WebThe study by Goldschmidt and colleagues included 81 patients with relapsed DLBCL, which occurred mostly in the first year after completion of therapy. 16 They found that stage, B symptoms, and prognostic score did not affect the way in which the relapse was detected (clinically vs by routine imaging), but extranodal involvement and timing of …

Did you know?

WebAug 30, 2005 · Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Briere J, Moskowitz CH, Schmitz N. Salvage … WebSpine 2010 35 E1221E1229 CrossRef 78 Avrahami E Tadmor R Dally O Hadar H Early from PHYS 111 at University of Toronto

WebNov 3, 2016 · Submitted April 28, 2009; accepted June 12, 2009; published online ahead of print at www.jco.org on October 5, 2009. Authors’ disclosures of potential con-ﬂicts of interest and author contribu-tions are found at the end of this article. Corresponding author: Motoko Yamaguchi, MD, PhD, Department of Hematology and Oncology, Mie Univer- WebFilter issues by Issue archive. 2024 - Volume 41. 2024 - Volume 40. 2024 - Volume 39. 2024 - Volume 38. 2010 - 2024. 2000 - 2009. 1990 - 1999. 1980 - 1989.

WebApr 12, 2024 · Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to the care of patients with cancer. Journal of Clinical Oncology Skip to main content Log In submission complete icon Submit envelope E-Alerts cart Cart WebMar 30, 2024 · Bortezomib, another proteasomal inhibitor, was combined with R-DA-EPOCH in 27 patients with R/R DLBCL with 83% ORR and 42% CRR in non-GCB DLBCL as compared with 13% ORR and 7% CRR in GCB DLBCL. 17 A phase 1 study evaluating ibrutinib in doses up to 840 mg daily in combination with R-ICE in R/R DLBCL showed impressive results …

WebNov 22, 2016 · J Clin Oncol. 2010;28(27):4184-90. Thieblemont C et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage …

WebAug 18, 2024 · J Clin Oncol. 2010;28(27):4184–90. CrossRef PubMed PubMed Central Google Scholar Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2024;38(2):155–65. drax half year resultsWebSep 20, 2010 · Journal of Clinical Oncology: Vol 28, No 27 Vol. 28, No. 27, September 20, 2010 EDITORIALS Is It Time to ReSET the Standard for Estrogen Receptor Testing in … drax group sharesWeb2 days ago · 1.Introduction 1.1.Immunotherapy for head and neck neoplasms. Head and neck neoplasms are the sixth most common malignant tumors in the world, with approximately 830,000 patients developing head and neck neoplasms each year [1].It is a general term for a class of cancers with a similar incidence and treatment plan, including … drax from the galaxyWebJul 3, 2024 · J Clin Oncol, 2010,28 (27):4184–4190 Article Google Scholar Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study, Haematologica, 2008,93 (12):1829–1836 Article CAS Google Scholar drax greenwashing filesWebJul 19, 2024 · Fifteen patients were treated after failure to CART therapy. Common adverse events of the whole group were neutropenia (28.4%), CRS (27.4%), hypophosphatemia … drax hero forgeWebSep 9, 2015 · The two most common EGFR mutations account for ∼90% of all mutation-positive NSCLC cases and are known to confer sensitivity to EGFR-TKIs: ... J Clin Oncol. 2010; 28:357–360. [PMC free article] [Google Scholar] ... 27. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer ... empty swing top bottlesWebJan 20, 2024 · J Clin Oncol. 2010;28(27):4184–90. Article Google Scholar Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from … drax haven power